Search results for "thrombosi"

showing 10 items of 634 documents

Development and Validation of a New Clinical Prediction Model of Catheter-Related Thrombosis Based on Vascular Ultrasound Diagnosis in Cancer Patients

2020

Background: Central venous catheters are convenient for drug delivery and improved comfort for cancer patients, but they also cause serious complications. The most common complication is catheter-related thrombosis (CRT). Objectives: This study aimed to evaluate the incidence and risk factors for CRT in cancer patients and develop an effective prediction model for CRT in cancer patients. Methods: The development of our prediction model was based on a retrospective cohort (n = 3,131) from the National Cancer Center. Our prediction model was confirmed in a prospective cohort from the National Cancer Center (n = 685) and a retrospective cohort from the Hunan Cancer Hospital (n = 61). The predi…

0301 basic medicinemedicine.medical_specialtylcsh:Diseases of the circulatory (Cardiovascular) systemMultivariate analysis030204 cardiovascular system & hematologyCardiovascular Medicinecathetersnomogram03 medical and health sciences0302 clinical medicineInternal medicinemedicinecancerRisk factorProspective cohort studythrombosisOriginal ResearchReceiver operating characteristicbusiness.industryCancerRetrospective cohort studyNomogrammedicine.disease030104 developmental biologyrisk factorlcsh:RC666-701CohortCardiology and Cardiovascular MedicinebusinessFrontiers in Cardiovascular Medicine
researchProduct

Comparison of Unfractionated Versus Low Molecular Weight Heparin for Deep Vein Thrombosis Prophylaxis During Breast and Pelvic Cancer Surgery: Effica…

1998

In a prospective, double-blind randomized trial the efficacy and safety of low molecular weight heparin and un fractionated heparin were compared for the prevention of post operative deep vein thrombosis in patients undergoing major surgery for breast and pelvic cancer. Three hundred fifty-eight patients were randomly allocated to the two treatment groups. Thirty-four of these were excluded from the study. Of the re maining 324 patients, 164 received 5000 IU unfractionated heparin three times daily and 160 received 3000 anti-Xa units of low molecular weight heparin once daily. Treatment was started 2 to 5 hours preoperatively and continued for 7 days. The occurrence of deep vein thrombosis…

0301 basic medicinemedicine.medical_specialtymedicine.drug_classDeep veinVenographyLow molecular weight heparin030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawMedicinePlethysmographmedicine.diagnostic_testbusiness.industryHematologyGeneral MedicineHeparinmedicine.diseaseThrombosisSurgery030104 developmental biologymedicine.anatomical_structureRelative riskAnesthesiabusinessmedicine.drugClinical and Applied Thrombosis/Hemostasis
researchProduct

Specialized regulatory T cells control venous blood clot resolution through SPARC.

2020

Abstract The cells and mechanisms involved in blood clot resorption are only partially known. We show that regulatory T cells (Tregs) accumulate in venous blood clots and regulate thrombolysis by controlling the recruitment, differentiation and matrix metalloproteinase (MMP) activity of monocytes. We describe a clot Treg population that forms the matricellular acid– and cysteine-rich protein SPARC (secreted protein acidic and rich in cysteine) and show that SPARC enhances monocyte MMP activity and that SPARC+ Tregs are crucial for blood clot resorption. By comparing different treatment times, we define a therapeutic window of Treg expansion that accelerates clot resorption.

0301 basic medicinemedicine.medical_treatmentImmunologyPopulation030204 cardiovascular system & hematologyMatrix metalloproteinaseBiochemistryT-Lymphocytes RegulatoryMonocytes03 medical and health sciences0302 clinical medicinemedicineAnimalsOsteonectinThrombuseducationVenous Thrombosiseducation.field_of_studyChemistryMonocyteFibrinolysisCell BiologyHematologyVenous bloodThrombolysismedicine.diseaseMatrix MetalloproteinasesResorptionCell biologyMice Inbred C57BL030104 developmental biologymedicine.anatomical_structureCysteineBlood
researchProduct

In Vivo Cardiotoxicity Induced by Sodium Aescinate in Zebrafish Larvae

2016

Sodium aescinate (SA) is a widely-applied triterpene saponin product derived from horse chestnut seeds, possessing vasoactive and organ-protective activities with oral or injection administration in the clinic. To date, no toxicity or adverse events in SA have been reported, by using routine models (in vivo or in vitro), which are insufficient to predict all aspects of its pharmacological and toxicological actions. In this study, taking advantage of transparent zebrafish larvae (Danio rerio), we evaluated cardiovascular toxicity of SA at doses of 1/10 MNLC, 1/3 MNLC, MNLC and LC10 by yolk sac microinjection. The qualitative and quantitative cardiotoxicity in zebrafish was assessed at 48 h p…

0301 basic medicinesodium aescinateEmbryo NonmammalianHeart malformationDrug Evaluation PreclinicalPharmaceutical Science010501 environmental sciencesPharmacology01 natural sciencesAnalytical ChemistryHeart RateDrug DiscoveryToxicity Tests ChronicZebrafishYolk SacbiologyCommunicationHeartLC10medicine.anatomical_structureChemistry (miscellaneous)LarvaToxicityMolecular MedicineHeart Defects CongenitalMicroinjectionscardiotoxicityHemorrhagelarvaelcsh:QD241-44103 medical and health scienceslcsh:Organic chemistryIn vivoHeart ratemedicineMNLCAnimalsPhysical and Theoretical ChemistryYolk sacAdverse effect0105 earth and related environmental sciencesCardiotoxicityDose-Response Relationship DrugOrganic ChemistryThrombosisSaponinsbiology.organism_classificationzebrafishTriterpenes030104 developmental biologyMolecules
researchProduct

Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes

2014

OBJECTIVES: Atrial fibrillation (AF) is the most common cardiac rhythm disorder with a significant health burden. The aim of this study was to characterise patients with recently diagnosed AF and to estimate the rates of comorbidities and outcome events requiring hospitalisation in routine clinical practice. DESIGN: Pharmacoepidemiological cohort study using observational data. METHODS/SETTING: This study included 16 513 patients with a first diagnosis of AF between 1 January 2005 and 28 February 2010 (newly diagnosed patients) using data from the UK Clinical Practice Research Datalink (CPRD) linked to Hospital Episode Statistics (HES) and the Office for National Statistics mortality data. …

1683AdultMalemedicine.medical_specialtyPediatricsmedicine.drug_classPopulationCardiologyHemorrhageCardiovascular MedicineCohort StudiesYoung AdultAtrial FibrillationEpidemiologymedicine1724Humans1506educationStrokeAgedAged 80 and overeducation.field_of_studybusiness.industryResearchIncidenceIncidence (epidemiology)WarfarinAnticoagulantsThrombosisGeneral MedicineMiddle AgedVitamin K antagonistmedicine.disease1692Cardiovascular DiseasesEmergency medicineFemaleWarfarinDiagnosis codebusinessCohort studymedicine.drug
researchProduct

Plasma Antithrombin Values Are Significantly Decreased in Coronavirus Disease 2019 (COVID-19) Patients with Severe Illness

2020

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Plasma AntithrombinSeverity of Illness IndexAntithrombinsCoronavirus Disease 2019medicineHumansThrombophiliaProspective StudiesPlasma Antithrombin Coronavirus Disease 2019 COVID-19business.industryHeparinSARS-CoV-2AntithrombinAnticoagulantsCOVID-19ThrombosisHematologyDisseminated Intravascular CoagulationVirologyCross-Sectional StudiesbusinessCardiology and Cardiovascular Medicinemedicine.drug
researchProduct

Invited commentary to: ADAMTS13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19 by T…

2021

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Letter to the Editors-in-ChiefHematologyAbnormal distributionVirologyVon Willebrand factor multimersADAMTS13Thrombosis ResearchMedicineIn patientbusinessThrombosis Research
researchProduct

The Millennial Generation of Thrombosis and Hemostasis

2020

2019-20 coronavirus outbreakHemostasisCoronavirus disease 2019 (COVID-19)business.industry10031 Clinic for AngiologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2720 Hematology610 Medicine & healthThrombosisHematologyBioinformaticsmedicine.diseaseThrombosisHemostasisMedicineHumansbusinessHämostaseologie
researchProduct

Atypical thrombosis associated with VaxZevria (R) (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres

2021

The current COVID-19 pandemic is an exceptional health situation including for drug use. As there was no known effective drug for COVID-19 at the beginning of the pandemic, different candidates were proposed. In this short article, we present the French public pharmacovigilance activities during this health crisis. Although COVID-19 is a confounding factor per se, owing to its potential for multi-organ damage including the heart and kidney, the quality of the transmitted data in adverse drug reaction reports, the timeliness of feedback from clinicians, and the real-time pharmacological and medical analysis by the French network of the regional pharmacovigilance centers made it possible to s…

2019-20 coronavirus outbreakTime FactorsCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[SDV]Life Sciences [q-bio]Letter to EditorAntiviral AgentsPharmacovigilancePharmacovigilancemedicineAdverse Drug Reaction Reporting SystemsHumansPharmacology (medical)PandemicsComputingMilieux_MISCELLANEOUSCovid-19 vaccineSARS-CoV-2business.industryCOVID-19VaxZevria®medicine.diseaseAtypical thrombosisThrombosisVirology[SDV] Life Sciences [q-bio]Anti-PF4 antibodiesFrancebusinessThrombopenia
researchProduct

Coronavirus Disease 2019–Associated Coagulopathy

2021

Patients with the severe form of coronavirus disease 2019 (COVID-19) have been frequently found to suffer from both arterial and venous thrombotic events due to the perpetuation of a hypercoagulable state. This phenomenon, termed COVID-19-associated coagulopathy (CC), is now considered a major component of the pathophysiology of this novel infectious disease, leading to widespread thrombosis. While at first, the vascular insults may be limited to the pulmonary microvasculature, as the disease progresses, systemic involvement occurs, culminating in distant organ thrombosis and multi-organ dysfunction syndrome. In this review article, we discuss recent insights into the pathophysiologic mecha…

ARDSPAI-1 Plasminogen Activator Inhibitor 1VTE venous thromboembolismDiseaseReview030204 cardiovascular system & hematologyCoronavirus Disease 20190302 clinical medicineCoagulopathy030212 general & internal medicineDIC disseminated intravascular coagulationDisseminated intravascular coagulationCOVID-19 Coronavirus disease 2019DVT deep vein thrombosisGeneral MedicineBlood Coagulation DisordersThrombosisICU intensive care unitTMA thrombotic microangiopathyDisease ProgressionCoronavirus Disease 2019 COVID-19 CoagulopathyVWF von Willebrand factormedicine.medical_specialtyThrombotic microangiopathyACE2 angiotensin-converting enzyme 2SARS-CoV-2 severe acute respiratory syndrome coronavirus 203 medical and health sciencesmedicineCoagulopathyHumansIntensive care medicineLY30 lysis at 30 minutesARDS acute respiratory distress syndromeHemostasisNO nitric oxideCoagulationbusiness.industrySARS-CoV-2COVID-19Thrombosismedicine.diseasetPA tissue plasminogen activatorReview articleIL interleukinCoronavirusVascular DisorderPE pulmonary embolismTF tissue factorbusinessCC COVID-associated coagulopathyMayo Clinic Proceedings
researchProduct